Sarepta Therapeutics Q3 Adj $0.37 Beats $(1.33) Estimate, Sales $331.82M Beat $285.83M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sarepta Therapeutics reported Q3 earnings of $0.37 per share, beating the analyst consensus estimate of $(1.33) by 127.82%. This is a 146.25% increase over losses of $(0.80) per share from the same period last year. The company also reported quarterly sales of $331.82 million, beating the analyst consensus estimate of $285.83 million by 16.09%. This is a 44.10% increase over sales of $230.27 million the same period last year.
November 01, 2023 | 9:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sarepta Therapeutics reported strong Q3 earnings and sales, significantly beating analyst estimates. This positive financial performance could lead to a short-term increase in the company's stock price.
Sarepta Therapeutics reported Q3 earnings and sales that significantly beat analyst estimates. This strong financial performance indicates that the company is performing well, which could make the stock more attractive to investors and lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100